Home Icon

Loading, Please Wait...

Isoray To Spotlight Cesium-131 Advances in Treating Hard to Treat Cancers at the American Society for Radiation Oncology Annual Meeting 

1020 Days ago

RICHLAND, WASHINGTON, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced today that it will spotlight the growing cancer treatment applications of Cesium-131 at the American Society for Radiation Oncology (ASTRO) annual meeting. The meeting will be held September 15-18 at McCormick Place in Chicago, Illinois.

During the meeting, attendees will have the opportunity to learn about the mounting body of clinical evidence illustrating the expanding use of Cesium-131, now known as Cesium BluTM, and its effectiveness in treating recurrent brain cancers including meningiomas and brain metastases.

Attendees will also get a first-hand look at the innovative Blu Build real-time Cesium-131 internal radiation therapy delivery system. Blu Build is believed to be the first new delivery system in years designed specifically for prostate internal radiation therapy. The delivery system enables doctors to deliver a high radiation dose to the targeted prostate cancer and limits the impact on the surrounding areas compared to other treatment options. Blu Build is the latest advance in the application of Cesium-131 in treating prostate cancer. State-of-the-art internal radiation isotope Cesium Blu has been the subject of an increasing number of publications detailing its efficacy in treating prostate cancer.

Isoray representatives will be at Booth #2612 to discuss recent developments with attendees regarding clinical applications where Cesium-131 has been found to be a potent, valuable option for clinicians and their patients. Isoray is the only producer of Cesium-131 brachytherapy, which expands internal radiation treatment for prostate and difficult to treat brain, gynecological, lung, head and neck, and esophageal cancers.

About Isoray
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium Blu by visiting www.isoray.com. Join us onFacebook and follow us on Twitter.

Safe Harbor Statement
Statements in this news release about Isoray's future expectations, including: the benefits of renaming our product “Cesium Blu, the advantages of Blu Build, whether interest in and use of our Cesium Blu products will increase or continue, whether use of Cesium-131 in non-prostate applications will continue to increase revenue, whether further manufacturing and production process improvements will be completed or will result in lower costs, whether our market presence and growth will continue, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing Isoray, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, market acceptance and recognition of our rebranded products, our ability to successfully manufacture, market and sell our Blu Build products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released that support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards, the success of our sales and marketing efforts, changes in reimbursement rates, the procedures and regulatory requirements mandated by the FDA for 510(k) approval and reimbursement codes, changes in laws and regulations applicable to our products, the scheduling of physicians who either delay or do not schedule patients in periods anticipated, the use of competitors' products in lieu of our products, less favorable reimbursement rates than anticipated for each of our products, and other risks detailed from time to time in Isoray's reports filed with the SEC. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  

Media and Public Relations: Sharon Schultz (302) 539-3747
Investor Relations: Mark Levin (501) 255-1910

We Are Diffrent
Is your business listed correctly on America’s largest city directory network of 1,000 portals? Find your City Portal